采用新型Hugo机器人辅助手术系统进行机器人辅助根治前列腺切除术（RARP）的临床数据很少。我们报道了2022年2月至11月在比利时奥斯特（OLV）医院接受RARP ± 扩展盆腔淋巴结切除术（ePLND）的112名连续患者的手术结果。中位年龄为65岁（四分位距[IQR] 60-70），中位术前前列腺特异性抗原（PSA）为7.9 ng / ml（5.8-10.7）。38名患者（34％）在前列腺活检中被诊断为国际泌尿病理学会分级组别≥3级肿瘤。在术前磁共振成像中，26名（23％）患者怀疑存在前列腺外病变。手术时间的中位数为180分钟（IQR 145-200），27名男性（24％）接受了ePLND。在最终病理检查中，有34名患者（31％）存在前列腺外病变，有10名（9％）有阳性切缘。切除的淋巴结的中位数为15个（IQR 9-19）。在第一次手术后PSA数据可用的男性中，88％（60/68）的PSA检测结果为低于0.1 ng / ml。恢复尿液连续性（UC）的概率为36％（95％置信区间[CI] 28-47％）1个月，81％（95％ CI 72-89％）3个月。UC恢复的中位时间为36天（95％ CI 34-44）。这是首次报道使用Hugo RAS机器人系统进行前列腺癌RARP患者的尿液连续性恢复和手术病理学数据。期待未来更长时间跟踪的研究。患者摘要：我们报道了在我们机构使用Hugo RAS机器人系统进行机器人辅助患者的前列腺癌手术切除的手术结果。在我们的经验中，该平台在手术结果和早期恢复尿液连续性方面提供了充分的结果。期待更长时间跟踪的研究。版权所有©2023年欧洲泌尿外科协会。由Elsevier B.V.出版。保留所有权利。

Clinical data on robot-assisted radical prostatectomy (RARP) performed with the new Hugo robot-assisted surgery (RAS) system are scarce. We described surgical outcomes of 112 consecutive patients who underwent RARP ± extended pelvic lymph-node dissection (ePLND) at OLV Hospital (Aalst, Belgium) between February and November 2022. The median age was 65 yr (interquartile range [IQR] 60-70) and median preoperative prostate-specific antigen (PSA) was 7.9 ng/ml (5.8-10.7). Thirty-eight patients (34%) had International Society of Urological Pathology grade group ≥3 tumor on prostate biopsy. On preoperative magnetic resonance imaging, 26 (23%) patients had a suspicion of extraprostatic disease. The median operative time was 180 min (IQR 145-200) and 27 men (24%) underwent ePLND. On final pathology, 34 patients (31%) had extraprostatic disease and ten (9%) had positive surgical margins. The median number of nodes removed was 15 (IQR 9-19). Among men with data available on the first PSA after surgery, 88% (60/68) had undetectable PSA (<0.1 ng/ml). The probability of urinary continence (UC) recovery was 36% (95% confidence interval [CI] 28-47%) at 1 mo and 81% (95% CI 72-89%) at 3 mo. The median time to UC recovery was 36 d (95% CI 34-44). This is the first report of data on UC recovery and surgical pathology for patients undergoing RARP for prostate cancer performed with the Hugo RAS robotic system. Future investigations with longer follow-up are awaited. PATIENT SUMMARY: We describe surgical outcomes of patients undergoing robot-assisted surgical removal of the prostate for cancer performed with the Hugo RAS robotic system at our institution. In our experience this platform provided adequate results in terms of surgical results and early recovery of urinary continence. Studies with longer follow-up are awaited.Copyright © 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.